Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study |
Apr 2019 |
Haematologica |
Aplastic Anemia |
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
Mar 2019 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
Mar 2019 |
National Cancer Institute |
Myelodysplastic Syndromes (MDS) |
Clonal Hematopoiesis and therapy related MDS/AML |
Mar 2019 |
Best Practice & Research. Clinical Heamatology |
Myelodysplastic Syndromes (MDS) |
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
Mar 2019 |
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. |
Mar 2019 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. |
Feb 2019 |
Biol Blood Marrow Transplant. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. |
Feb 2019 |
Cancer Med |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia. |
Feb 2019 |
Haematologica |
Aplastic Anemia |
Rethinking clinical trial endpoints in myelodysplastic syndromes. |
Jan 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |